Family History of Dilated Cardiomyopathy among Patients with Heart Failure from the HF‐ACTION Genetic Ancillary Study. Issue 3 (24th April 2013)

• Record Type: Journal Article
• Authors: Hudson, Laura; Morales, Ana; Mauro, Ana Clara; Whellan, David; Adams, Kirkwood F.; O'Connor, Christopher M.; Hershberger, Ray E.
• Is Part Of: Clinical and translational science. Volume 6:Issue 3(2013)
• Page Start: 179
• Page End: 183
• Publication Date: 2013-04-24
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12041
• Languages: English
• ISSNs: 1752-8054

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="cts12041-sec-0010" sec-type="section"> <title>Background</title> <p>The value of family history (FH) is well established, but its sensitivity to detect familial dilated cardiomyopathy (FDC) has been infrequently examined.</p> </sec> <sec id="cts12041-sec-0020" sec-type="section"> <title>Methods</title> <p>A genetic ancillary study was created as a component of the HF‐ACTION trial, a multicenter, prospective, randomized clinical trial of exercise in patients with heart failure and an ejection fraction <35%. A FH‐based study using a structured questionnaire mailed to all consenting individuals was incorporated into the genetic ancillary. FH responses were analyzed for dilated cardiomyopathy (DCM) in family members.</p> </sec> <sec id="cts12041-sec-0030" sec-type="section"> <title>Results</title> <p>Of the 741 individuals with data available, 358 (48.3%) had nonischemic and 383 (51.6%) had ischemic etiology, and of these 164 (45.8%) and 201 (52.4%), respectively, returned evaluable questionnaires. Of those with nonischemic etiology, 14/164 (8.5%) reported at least one first‐degree family member with DCM or an enlarged heart; another 21/164 (12.8%) reported a FH of "cardiomyopathy, " a less specific term to indicate DCM.</p> </sec> <sec id="cts12041-sec-0040" sec-type="section"> <title>Conclusion</title> <p>At least 8.5% of patients with nonischemic etiology in the HF‐ACTION genetic ancillary study provided FH indicating familial DCM, information important to inform further genetic analyses of this cohort and to plan other studies.</p> </sec> </abstract>